Recent Advances in Nanocarriers for Pancreatic Cancer Therapy

1st Edition - October 22, 2023
Editors: Prashant Kesharwani, Neelima Gupta
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 1 4 2 - 8
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 5 2 8 8 - 7

Recent Advances in Nanocarriers for Pancreatic Cancer Therapy reviews thriving strategies concerning pancreatic cancer therapy, thoroughly describing the most recent developme… Read more

Purchase options

SUSTAINABLE DEVELOPMENT

Innovate. Sustain. Transform.

Save up to 30% on top Physical Sciences & Engineering titles!

Explore now

Physical science & engineering for sustainable development book covers

Institutional subscription on ScienceDirect

Request a sales quote

Recent Advances in Nanocarriers for Pancreatic Cancer Therapy reviews thriving strategies concerning pancreatic cancer therapy, thoroughly describing the most recent developments in emerging modern drug delivery systems focused on, and derived from, nanotechnology. By providing a holistic understanding of the molecular pathways, conventional therapy and novel nanocarriers mediated drug delivery against pancreatic cancer, this work can be considered a complete package. The book offers a solution to the dissemination of data from a broad range of resources by providing an overview of the molecular pathways and conventional therapy of pancreatic cancer, the application of various nanocarriers, and more.

This book equips scientists, clinicians and students to make rational treatment approaches based on nanomedicine for improving and extending the human life against pancreatic cancer.

Cover image
Title page
Table of Contents
Copyright
Dedication
List of contributors
About the editors
Preface
Acknowledgments
Part A: Overview, molecular pathways and conventional therapy of pancreatic cancer
Chapter 1. An overview of the anatomy, physiology, and pathology of pancreatic cancer
Abstract
1.1 Pancreas anatomy
1.2 Pancreas physiology
1.3 Pancreas cancer pathology
1.4 Conclusion
References
Chapter 2. Different combination therapies pertaining to pancreatic cancer
Abstract
2.1 Introduction
2.2 Carrier-free combination therapy in pancreatic cancer treatment
2.3 Nanoparticle-mediated combination therapy in pancreatic cancer treatment
2.4 Combination treatment with chimeric antigen receptor T cells and oncolytic viruses
2.5 Compounds of natural origin and combination therapy in pancreatic cancer treatment
2.6 Conclusions and perspectives
References
Part B: Application of various nanocarriers for the management of pancreatic cancer
Chapter 3. Potential application of nanotechnology in the treatment and overcoming of pancreatic cancer resistance
Abstract
3.1 Introduction
3.2 Current therapeutics for pancreatic cancer
3.3 Drug resistance as a pitfall
3.4 Nanotechnology as a therapeutic window
3.5 Conclusion
References
Chapter 4. Application of hydrogel-based drug delivery system for pancreatic cancer
Abstract
4.1 Introduction
4.2 Pancreatic cancer
4.3 Physiology
4.4 Limitations
4.5 Hydrogels
4.6 Types of polymers used in hydrogels
4.7 Preparation of hydrogels
4.8 Types of some common hydrogels
4.9 Applications of hydrogels against pancreatic cancer
4.10 Diagnosis
4.11 Conclusion and future outlook
References
Chapter 5. Liposome- and niosome-based drug delivery for pancreatic cancer
Abstract
5.1 Introduction
5.2 Liposome-based drug delivery
5.3 Liposomal drug delivery platforms for pancreatic cancer
5.4 Targeted nanoliposomes for pancreatic cancer treatment
5.5 Stimuli-responsive liposomal nano-formulations for pancreatic cancer
5.6 Clinical studies of liposomal formulation for pancreatic cancer treatment
5.7 Niosome-based drug delivery
5.8 Conclusion
Declaration of competing interest
References
Chapter 6. Micelles-based drug delivery for pancreatic cancer
Abstract
6.1 Introduction
6.2 Micellar uptake mechanism
6.3 Polymeric micelles and their types
6.4 Pancreatic cancer–targeting sites for micelles
6.5 Small interfering RNA-loaded micelles for pancreatic cancer therapy
6.6 Polymeric micelles in clinical studies for pancreatic cancer
6.7 Conclusion
References
Chapter 7. Theranostic nanoparticles in pancreatic cancer
Abstract
7.1 Introduction
7.2 Metal nanoparticles
7.3 Polymeric nanoparticles
7.4 Carbon nanoparticles
7.5 Conclusion
References
Chapter 8. Recent advances in nanocarriers for pancreatic cancer therapy
Abstract
8.1 Introduction
8.2 Polymeric nanoparticles
8.3 Diagnosis
8.4 Surgical management
8.5 Medical management
8.6 Conclusion
References
Chapter 9. Metallic nanoparticles-based drug delivery for pancreatic cancer
Abstract
9.1 Introduction
9.2 Gold nanoparticles
9.3 Silver nanoparticles
9.4 Iron oxide nanoparticles
9.5 Other metallic nanoparticles (Pd, Pt, CuO, ZnO, TiO2)
9.6 Mesoporous silica nanoparticles
9.7 Conclusion
Acknowledgments
Conflicts of interest
References
Chapter 10. Empowering treatment strategies for pancreatic cancer by employing lipid nanoparticle-driven drug delivery
Abstract
10.1 Introduction
10.2 Symptoms and risk factors of pancreatic cancer
10.3 Lipid nanoparticles
10.4 Solid lipid nanoparticles
10.5 Limitations of solid lipid nanoparticles and way to overcome
10.6 High pressure-induced drug degradation
10.7 Lipid crystallization and drug incorporation
10.8 Several colloidal species coexist
10.9 Nanostructured carriers of lipid (solid lipid nanoparticles and nanostructured lipid carriers)
10.10 Applications of solid lipid nanoparticles in pancreatic cancer
10.11 Conclusion
References
Chapter 11. Solid lipid nanoparticle-based drug delivery for pancreatic cancer
Abstract
11.1 Introduction
11.2 Lipid classifications for solid–lipid nanoparticle synthesis
11.3 Preparations techniques of solid lipid-based nanoparticles
11.4 Role of pancreatic lipase and lipid nanoparticle in pancreatic cancer therapy
11.5 Enhancing cancer therapeutic efficacy with lipid-based nanoparticles
11.6 Future aspects
References
Chapter 12. Dendrimers and carbon nanotubes-based drug delivery for pancreatic cancer
Abstract
12.1 A brief overview of pancreatic cancer
12.2 Drug delivery for cancer therapy
12.3 Carbon nanotubes
12.4 Dendrimers
12.5 Dendrimers and carbon nanotubes-based drug delivery for pancreatic cancer
12.6 Conclusion
References
Part C: Recent advances and future prospective for pancreatic cancer
Chapter 13. Personalized medicine and new therapeutic approach in the treatment of pancreatic cancer
Abstract
13.1 Introduction
13.2 Could personalized medicine transform healthcare?
13.3 The role of personalized medicine in pancreatic cancer
13.4 Recent progress in personalized medicine for pancreatic cancer therapy
13.5 The molecular landscape of pancreatic cancer
13.6 Genomic subgroups
13.7 Transcriptomic subgroup
13.8 Predictive markers of pancreatic cancer for personalized therapy
13.9 Examples of precision medicine in pancreatic cancer
13.10 The advantages of microfluidic devices
13.11 General scheme of producing a pancreatic organoid
13.12 Some applications of pancreatic organoids
13.13 The quantitative imaging methods for pancreatic cancer diagnosis, prognosis, and prediction
13.14 Challenges and innovations in personalized medicine care
13.15 Challenges in the treatment of pancreatic cancer
13.16 The challenges from an oncologist’s perspective
13.17 Opportunities for personalized therapy in the near future
13.18 Conclusion
Declarations of interest
References
Chapter 14. Clinical practice guidelines for interventional treatment of pancreatic cancer
Abstract
14.1 The definition of pancreatic cancer and its classification in clinic
14.2 Incidence and epidemiology and risk factors
14.3 Surgical treatment of pancreatic cancer
14.4 Nonsurgical therapies
14.5 Treatment in metastatic patient
Grant
Conflict of interest
References
Chapter 15. Aptamer-mediated nano-therapy for pancreatic cancer
Abstract
15.1 Introduction
15.2 Nanotechnology as a novel cancer therapeutic strategy
15.3 Aptamers as an advance targeted strategy in cancer diagnosis and treatment
15.4 Aptamer design approaches
15.5 Methods for coupling aptamers to nanoparticles
15.6 Tumor markers for pancreatic cancer
15.7 Aptamers against pancreatic cancer
15.8 Aptamers in clinical trials for pancreatic cancer
15.9 Aptamer-functionalized nanocarriers against pancreatic cancer
15.10 Conclusion
Conflict of interest
References
Chapter 16. Photodynamic therapy for pancreatic cancer
Abstract
16.1 Pancreatic cancer
16.2 Principles of photodynamic therapy
16.3 Elements of photodynamic therapy
16.4 Photodynamic therapy in pancreatic cancer
16.5 Nanoparticles mediated photodynamic therapy for pancreatic cancer
16.6 Combination of photodynamic therapy with other therapies in pancreatic cancer treatment
16.7 Summary and outlook
Declaration of competing interest
References
Chapter 17. Future prospect of nano-based drug delivery approaches against pancreatic cancer and expected pitfalls of the technology
Abstract
17.1 Introduction
17.2 Conventional therapy for pancreatic cancer
17.3 The prospects of nanotechnology in pancreatic cancer treatment
17.4 Applications of various types of nano-based drug delivery systems for pancreatic cancer therapy
17.5 Challenges of nano-based drug delivery system for pancreatic cancer therapy
17.6 Conclusion and future perspective
Acknowledgements
References
Index

Prashant Kesharwani

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.

Affiliations and expertise

Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

Neelima Gupta

Prof. Neelima Gupta presently works as a vice chancellor of Dr. Harisingh Gour Vishwavidyalaya Sagar (A Central University), Madhya Pradesh, India. She is a global leader having visited the five continents of the world, including countries like the United States, UK, Japan, Germany, France, Poland, Hong Kong, Thailand, Egypt, China, Singapore, Egypt, and Australia. She is the recipient of more than 70 awards and has published 216 research papers, is the author/editor of 9 books, and has adjudicated more than 150 PhD theses in India and abroad. She has worked extensively on parasite taxonomy, aquatic toxicology, and pollution load of the Ramganga (Kalagarh to Kannauj) and Ganga (Haridwar to Kanpur) rivers, and fish health. Research contributions include morpho-molecular–SEM taxonomy and protein profile based on 60 species of 22 genera (51 new species, 3 subspecies), and 7 GenBank submissions (GenBank: NIH genetic sequence database). She is a pioneer in the Atmanirbhar Bharat Movement launched by the Government of India.

Affiliations and expertise

Vice Chancellor, Dr. Harisingh Gour Sagar University (A Central University), Sagar, Madhya Pradesh, India

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health